Asset Details
Do you wish to reserve the book?
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Do you wish to request the book?
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
2021
Overview
All coronaviruses known to have recently emerged as human pathogens probably originated in bats
1
. Here we use a single experimental platform based on immunodeficient mice implanted with human lung tissue (hereafter, human lung-only mice (LoM)) to demonstrate the efficient in vivo replication of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as two endogenous SARS-like bat coronaviruses that show potential for emergence as human pathogens. Virus replication in this model occurs in bona fide human lung tissue and does not require any type of adaptation of the virus or the host. Our results indicate that bats contain endogenous coronaviruses that are capable of direct transmission to humans. Our detailed analysis of in vivo infection with SARS-CoV-2 in human lung tissue from LoM showed a predominant infection of human lung epithelial cells, including type-2 pneumocytes that are present in alveoli and ciliated airway cells. Acute infection with SARS-CoV-2 was highly cytopathic and induced a robust and sustained type-I interferon and inflammatory cytokine and chemokine response. Finally, we evaluated a therapeutic and pre-exposure prophylaxis strategy for SARS-CoV-2 infection. Our results show that therapeutic and prophylactic administration of EIDD-2801—an oral broad-spectrum antiviral agent that is currently in phase II/III clinical trials—markedly inhibited SARS-CoV-2 replication in vivo, and thus has considerable potential for the prevention and treatment of COVID-19.
Human and bat coronaviruses replicate efficiently in immunodeficient mice implanted with human lung tissue, and treatment or prophylaxis using EIDD-2801 in this model suggests that this oral antiviral agent may be effective in preventing COVID-19.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/51
/ 14/28
/ 14/32
/ 14/63
/ 38/90
/ 38/91
/ 64/60
/ 82/51
/ Alveolar Epithelial Cells - immunology
/ Alveolar Epithelial Cells - pathology
/ Alveolar Epithelial Cells - virology
/ Alveoli
/ Animals
/ Antigens
/ Clinical Trials, Phase II as Topic
/ Clinical Trials, Phase III as Topic
/ COVID-19
/ COVID-19 - prevention & control
/ Cytidine - administration & dosage
/ Cytidine - analogs & derivatives
/ Female
/ Humanities and Social Sciences
/ Humans
/ Hydroxylamines - administration & dosage
/ Hydroxylamines - therapeutic use
/ Interferon Type I - immunology
/ Lungs
/ Male
/ Mice
/ Middle East respiratory syndrome
/ Science
/ Severe acute respiratory syndrome coronavirus 2
/ Testing
/ Viruses
